Home » News » Sanofi-Synthelabo unveils 2 new diabetic drugs

Sanofi-Synthelabo unveils 2 new diabetic drugs

Sanofi-Synthelabo (India) Pvt Ltd has launched two drugs for type-2 diabetes patients in India – Lyxumia (lixisenatide) and Zemiglo (gemigliptin). Lyxumia, a non-insulin injectable drug, is approved in over 70 countries and commercially launched in most EU countries, Sanofi-SynthelaboJapan, Brazil and Mexico, a company statement said. The company has filed an application for approval in the U.S..Zemiglo, oral tablet, has been approved in South Korea in 2012 and has had over three years of clinical experience. “The two additions to Sanofi India portfolio is our step forward in developing new solutions for people with type-2 diabetes,” said N.Rajaram, Country Head.



Don't be shellfish...Share on FacebookShare on Google+Share on LinkedInShare on StumbleUponPin on PinterestTweet about this on Twitter

Share and Enjoy

  • Facebook
  • Twitter
  • Delicious
  • LinkedIn
  • StumbleUpon
  • Add to favorites
  • Email
  • RSS

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Free WordPress Themes - Download High-quality Templates